Analysis and Commentary STEVEN GROSSMAN 3/6/21 Analysis and Commentary STEVEN GROSSMAN 3/6/21 Critical Supply Chains and the FDA Read More Analysis and Commentary STEVEN GROSSMAN 2/27/21 Analysis and Commentary STEVEN GROSSMAN 2/27/21 Questions (and Answers) About Current Political Issues Read More Analysis and Commentary STEVEN GROSSMAN 2/19/21 Analysis and Commentary STEVEN GROSSMAN 2/19/21 "FDA Exceptionalism," Redux (Again) Read More Analysis and Commentary STEVEN GROSSMAN 2/13/21 Analysis and Commentary STEVEN GROSSMAN 2/13/21 FDA-related Provision of House Reconciliation Bill Read More Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More Analysis and Commentary STEVEN GROSSMAN 1/29/21 Analysis and Commentary STEVEN GROSSMAN 1/29/21 Biden's Budget Request for FY 22 and Related Issues Read More Analysis and Commentary STEVEN GROSSMAN 1/21/21 Analysis and Commentary STEVEN GROSSMAN 1/21/21 Leadership and FDA Appropriation for FY 22 Read More Analysis and Commentary STEVEN GROSSMAN 1/16/21 Analysis and Commentary STEVEN GROSSMAN 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More Analysis and Commentary STEVEN GROSSMAN 1/8/21 Analysis and Commentary STEVEN GROSSMAN 1/8/21 Now We Know Who'll Be in Charge Read More Analysis and Commentary STEVEN GROSSMAN 12/10/20 Analysis and Commentary STEVEN GROSSMAN 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More Analysis and Commentary STEVEN GROSSMAN 11/19/20 Analysis and Commentary STEVEN GROSSMAN 11/19/20 Time to Give Thanks -- Once Again Read More Analysis and Commentary STEVEN GROSSMAN 11/12/20 Analysis and Commentary STEVEN GROSSMAN 11/12/20 Where $40 Million Might Go for FY 21 Read More Analysis and Commentary STEVEN GROSSMAN 11/8/20 Analysis and Commentary STEVEN GROSSMAN 11/8/20 What Happens in the Next Few Months? Read More Analysis and Commentary STEVEN GROSSMAN 10/31/20 Analysis and Commentary STEVEN GROSSMAN 10/31/20 Whether There Is or Whether There Isn't Read More Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Analysis and Commentary STEVEN GROSSMAN 10/16/20 Analysis and Commentary STEVEN GROSSMAN 10/16/20 Future Changes in Congressional Committees and the FDA Read More Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 3/6/21 Analysis and Commentary STEVEN GROSSMAN 3/6/21 Critical Supply Chains and the FDA Read More
Analysis and Commentary STEVEN GROSSMAN 2/27/21 Analysis and Commentary STEVEN GROSSMAN 2/27/21 Questions (and Answers) About Current Political Issues Read More
Analysis and Commentary STEVEN GROSSMAN 2/19/21 Analysis and Commentary STEVEN GROSSMAN 2/19/21 "FDA Exceptionalism," Redux (Again) Read More
Analysis and Commentary STEVEN GROSSMAN 2/13/21 Analysis and Commentary STEVEN GROSSMAN 2/13/21 FDA-related Provision of House Reconciliation Bill Read More
Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More
Analysis and Commentary STEVEN GROSSMAN 1/29/21 Analysis and Commentary STEVEN GROSSMAN 1/29/21 Biden's Budget Request for FY 22 and Related Issues Read More
Analysis and Commentary STEVEN GROSSMAN 1/21/21 Analysis and Commentary STEVEN GROSSMAN 1/21/21 Leadership and FDA Appropriation for FY 22 Read More
Analysis and Commentary STEVEN GROSSMAN 1/16/21 Analysis and Commentary STEVEN GROSSMAN 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More
Analysis and Commentary STEVEN GROSSMAN 1/8/21 Analysis and Commentary STEVEN GROSSMAN 1/8/21 Now We Know Who'll Be in Charge Read More
Analysis and Commentary STEVEN GROSSMAN 12/10/20 Analysis and Commentary STEVEN GROSSMAN 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More
Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 11/19/20 Analysis and Commentary STEVEN GROSSMAN 11/19/20 Time to Give Thanks -- Once Again Read More
Analysis and Commentary STEVEN GROSSMAN 11/12/20 Analysis and Commentary STEVEN GROSSMAN 11/12/20 Where $40 Million Might Go for FY 21 Read More
Analysis and Commentary STEVEN GROSSMAN 11/8/20 Analysis and Commentary STEVEN GROSSMAN 11/8/20 What Happens in the Next Few Months? Read More
Analysis and Commentary STEVEN GROSSMAN 10/31/20 Analysis and Commentary STEVEN GROSSMAN 10/31/20 Whether There Is or Whether There Isn't Read More
Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 10/16/20 Analysis and Commentary STEVEN GROSSMAN 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More
Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More
Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More
